# Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment

> **NCT02227238** · PHASE3 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 627 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** DTG
- **DRUG:** LPV/RTV
- **DRUG:** Two NRTIs

## Key facts

- **NCT ID:** NCT02227238
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-11
- **Primary completion:** 2017-08-02
- **Final completion:** 2022-02-14
- **Target enrollment:** 627 (ACTUAL)
- **Last updated:** 2023-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02227238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02227238, "Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02227238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*